EUVIMEDEUVIMED entdecken
Open Access

Genetically Engineered Cell Membrane-Coated Nanodrug for Targeted Treatment of Thyroid Cancer

Shaojie Xu iD, Xingyin Li, Youyun Peng, Xue Yang, Yuhang Su, Hanning Li, Sining Wang, Xin Huang iD, Xingrui Li, Yaying Du iD

Biomaterials Research · 01.01.2026 · 30

DOI: 10.34133/bmr.0358 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomaterials Research, online erschienen am 07.05.2026. Verfasst von Shaojie Xu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thyroid and Breast Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030…. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Knowledge Innovation Program of Wuhan-Shuguang Project, Bethune Charitable Foundation.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Thyroid cancer is the most common endocrine malignancy, particularly in patients with radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC), who have limited treatment options and poor clinical prognosis. In this study, doxorubicin and sorafenib were loaded into the photothermal conversion agent mesoporous polydopamine, forming mPDS. Tumor cell membrane coating engineering resulted in the formation of mPDS@CAR-M, significantly improving tumor targeting. After internalization by tumor cells, the loaded drugs are rapidly released under near-infrared laser irradiation. mPDS@CAR-M effectively inhibits tumor cell proliferation by enhancing oxidative stress, suppressing the PI3K–AKT–mTOR signaling pathway, and inducing cytotoxic autophagy. By activating harmful autophagy, mPDS@CAR-M further inhibits the epithelial–mesenchymal transition process, reducing tumor cell migration capacity. In vivo experiments showed that mPDS@CAR-M significantly reduced tumor volume, with its therapeutic efficacy closely related to the expression level of the targeted surface antigen. Therefore, mPDS@CAR-M demonstrates significant potential in the treatment of RAIR-DTC, providing a novel direction for further clinical exploration.

Autor:innen und Institutionen

  • Department of Thyroid and Breast Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
  • Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.

ORCID-Profile: Shaojie Xu, Xin Huang, Yaying Du

Förderung

  • National Natural Science Foundation of China
  • Knowledge Innovation Program of Wuhan-Shuguang Project
  • Bethune Charitable Foundation

Zitieren

APA

Xu, S., Li, X., Peng, Y., Yang, X., Su, Y., Li, H., Wang, S., Huang, X., Li, X., & Du, Y. (2026). Genetically Engineered Cell Membrane-Coated Nanodrug for Targeted Treatment of Thyroid Cancer. Biomaterials Research, 30. https://doi.org/10.34133/bmr.0358

Vancouver

Xu S, Li X, Peng Y, Yang X, Su Y, Li H, et al. Genetically Engineered Cell Membrane-Coated Nanodrug for Targeted Treatment of Thyroid Cancer. Biomaterials Research. 2026;30. doi:10.34133/bmr.0358

BibTeX
@article{Xu2026,
  author = {Xu, Shaojie and Li, Xingyin and Peng, Youyun and Yang, Xue and Su, Yuhang and Li, Hanning and Wang, Sining and Huang, Xin and Li, Xingrui and Du, Yaying},
  title = {Genetically Engineered Cell Membrane-Coated Nanodrug for Targeted Treatment of Thyroid Cancer},
  journal = {Biomaterials Research},
  year = {2026},
  volume = {30},
  doi = {10.34133/bmr.0358}
}
Kostenlos starten →